Wednesday, July 8, 2026

Drug profile · INN

tacrine hydrochloride

tacrine hydrochloride (COGNEX) is a cholinesterases; ache & bche inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tacrine hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

tacrine hydrochloride (COGNEX) is a cholinesterases; ache & bche inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN tacrine hydrochloride
Brand COGNEX
Mechanism Cholinesterases; ACHE & BCHE inhibitor
Target Cholinesterases; ACHE & BCHE
Route ORAL
Formulation CAPSULE

Mechanism of action

Cholinesterases; ACHE & BCHE inhibitor

Primary target: Cholinesterases; ACHE & BCHE

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. rivastigmine Nervous system (N06)
  2. rivastigmine tartrate Cholinesterases; ACHE & BCHE inhibitor

Frequently asked questions

What is tacrine hydrochloride?

tacrine hydrochloride (COGNEX) is a cholinesterases; ache & bche inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for tacrine hydrochloride?

COGNEX is a marketed brand name for tacrine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tacrine hydrochloride?

tacrine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.